Grabar Law Office files, as local counsel to Self-Insured Schools of California, an antitrust class action alleging that Defendants have conspired to fix and raise the prices for albuterol sulfate tablets sold in 2mg and 4mg dosages (referred to herein as “Albuterol Sulfate Tablets”) in the United States. The complaint alleges that Defendants’ conspiracy resulted in Plaintiff and the Class paying artificially inflated prices for Albuterol Sulfate Tablets. In fact, as alleged, between April and May 2013, the average purchase price for Albuterol Sulfate Tablets by retail community pharmacies increased 4,270%, from $0.10 to $4.37 per pill, for the 2mg dosage and 2,644%, from $0.16 to $4.39, for the 4mg dosage. During the one-year period from December 2012 to December 2013, the average price of Albuterol Sulfate Tablets paid to retailers increased by 1,746%, from $0.28 to $5.17. The timing and magnitude of the extraordinary increases were similar for the two primary manufacturers of Albuterol Sulfate Tablets. During this period, the average retail price of 2mg pills increased over 1,000% for Mylan (from $0.17 to $5.55) and Sun (from $0.30 to $4.42). The average retail price of 4mg pills similarly increased by over 1,000% for Mylan (from $0.21 to $5.85) and Sun (from $0.42 to $4.36). It is alleged that these massive price increases are extremely atypical and cannot be explained by traditional market forces.
